T he renin-angiotensin system and especially the angiotensin peptides play a central role in the pathophysiology of cardiovascular diseases.
inhibition of proliferation and growth. 6, 7 The activation of the Mas receptor by angiotensin peptides counteracted many effects of the AT1 receptor such as vasoconstriction. [8] [9] [10] Among these angiotensin peptides, the physiological and pathophysiological effects of Ang-II have been widely investigated. The role of Ang-II in systemic vascular resistance is now well established. 11 Although systemic vascular resistance is a common risk factor for CKD and heart failure, 12 the plasma concentration of Ang-II is not significantly different in patients with CKD or heart failure. However, recent advances in proteomic techniques offer the opportunity to analyze the peptidome and proteome of organ supernatants, for example, of stimulated adrenal glands, through the use of high-throughput and sensitive techniques. 13, 14 Thus, we may now be able to isolate, identify, and characterize as-yet unknown endogenous cofactors of angiotensin peptides.
Because Ang-II has a strong impact on the regulation of vascular tone but Ang-II plasma concentrations are not significantly altered in patients with CKD or heart failure, 10 we hypothesized that as-yet unknown endogenous cofactors of Ang-II are involved in the action of this peptide. Therefore, this study focused on the isolation, identification, and characterization of this endogenous cofactor modulating the effects of Ang-II.
Methods
A detailed description of the methods used is given in the online-only Data Supplement.
Isolation of VIF

Mechanical Disintegration and Extraction
Bovine adrenal glands were cut into equal pieces, snap-frozen in liquid nitrogen, and subsequently lyophilized. The freeze-dried adrenal glands were mechanically pulverized. The resulting mixture was homogenized and centrifuged.
Isolation of Granules From Bovine Adrenal Glands
Fresh bovine adrenal glands were obtained on ice from a local slaughterhouse and cleaned of lipid matter, and then the adrenal glands were dissected. The granules were obtained from the adrenal glands according to established techniques. 15, 16 For the extraction of VIF from the granules, carbachol was added. PBS was added to the control aliquot as a negative control condition. The supernatant was analyzed by electrospray-ionization (ESI) mass spectrometry (MS) as described below.
Enzymatic Digestion of Chromogranin-A
Chromogranin A was enzymatically digested as previously described. 17 Aliquots of the reaction mixture were removed and analyzed by ESI-MS as described above.
Chromatography
The supernatant was loaded onto different chromatographic columns (reverse-phase chromatography column, anion-exchange chromatography gel, analytic reverse-phase chromatography column). A stepwise gradient and linear gradients were used to elute the retained substances from the chromatography gel. The fractions were lyophilized and fractionation by the next chromatographically step. Each resulting fraction was screened for vasoregulatory properties by use of the bioassay of the isolated perfused rat kidney as described below.
Identification of VIF by MS Analyses
Matrix-Assisted Laser Desorption/Ionization MS
The lyophilized fractions from the reverse-phase chromatography affecting the vascular tone of the isolated perfused kidney were resuspended and prepared on a prestructured matrix-assisted laser desorption/ionization (MALDI) sample support using the affinity sample preparation 18 method. The fractions of interest were analyzed by MALDI time-of-flight MS (MALDI-TOF-MS) and MALDI-TOF/ TOF fragment ion analysis. Fragment ion spectra were recorded with the use of the LIFT option of the instrument. Peptide identification using the obtained fragment ion mass data was performed with the Mascot software package (Matrix Science, UK) and the RapiDeNovo sequencing tool (version 3.0.1, Bruker-Daltronic, Germany).
Electrospray-Ionization MS
In addition to the MALDI-MS, the fractions of interest were analyzed by using a liquid chromatography/electrospray ionization (ESI) MS/MS technique. The MS data were accumulated by the software HyStar 3.2 (Bruker-Daltonics, Germany) and analyzed by use of the Data Analysis 4.0 software (Bruker-Daltonics). Glutathione was used as an internal standard for calculation of the recovery rate.
Peptide Synthesis of VIF and Scrambled Peptides
After MS identification, the peptide VIF and the scrambled peptide were synthesized automatically by use of the solid-phase method and standard fluorenylmethyloxycarbonyl chloride chemistry in continuous flow modes.
Bioassays
Isolated Perfused Rat Kidney Bioassay
Male Wistar-Kyoto rats were anesthetized. After negative nociceptive reflexes were obtained, the abdominal cavity was opened. The aorta and the right kidney were isolated. The kidney was connected to the perfusion system after excision. The perfusion pressure was monitored continuously. The perfusion procedure generally followed the description given by van der Giet et al. 19 A perfusion of N-nitrol-arginine methyl ester (L-NAME) was carried out to analyze any involvement of endothelial dependence. α,β-Methylene-adenosine 5′-triphosphate (10 −5 mol/L) and Ang-II (10 −6 mol/L) were used as positive controls for vasoconstrictive response of the isolated kidney.
Isolated Aortic Ring Bioassay
Male Sprague-Dawley rats were dispatch by isoflurane overdose. The thoracic aorta was rapidly removed and divided into equal rings. The aortic rings were suspended in an automatic organ bath, and changes in force were recorded and analyzed. Each aortic ring was preloaded with 3 g and equilibrated for 60 minutes. After equilibration, the aortic rings were exposed to Ang-II. The compound C21 and synthetic peptide VIF were added to the perfusion solution of the precontracted rings. To block the nitric oxide-dependent effects, L-NAME was added and the variation in the response was recorded. At the end of the experiments, the viability of the aortic rings was determined by measuring the contraction to potassium chloride. Data are expressed as percentage of maximal contraction caused by Ang-II. Animal experiments were reviewed and approved by local authorities of the University RWTH Aachen (Germany) in accordance with the German animal protection law.
Pressure Myography
Experiments on freshly dissected carotid arteries from wild-type mice were performed by use of a pressure myograph. The synthetic peptide VIF buffer was dissolved in buffer and added to carotid arteries. Maximal constriction was induced by exchanging the bath solution with a solution containing phenylephrine. Maximum dilations were found to be achieved by using sodium nitroprusside. Data are given as percentages of maximal dilation to sodium nitroprusside or percentage of maximal constriction.
Human aortic smooth muscle cells were plated and cultured according to the manufacturer's recommendations. Human aortic smooth muscle cells were stimulated with varying VIF and human Ang-II concentrations as indicated. Total cell lysates were separated and detected with the appropriate antibodies. As primary antibody, anti-phosphorylated extracellular signal-regulated kinases 1/2 (ERK1/2; E-4) and anti-ERK2 (K-23) antibodies were used. As secondary antibody, horseradish peroxidase-conjugated anti-rabbit antibodies were used. Protein bands were visualized with a LAS 3000 Imager and quantified with the Aida Image Analyzer Software (Fuji/Raytest, Germany).
In Vivo Effects of Synthetic Peptide VIF
Wistar rats were used to investigate the effect of synthetic VIF in vivo. All animals had free access to standard rat diet and tap water ad libitum. Mean arterial pressure was measured in conscious animals by means of a tail-cuff sphygmomanometer. Five determinations were made, and the mean value was used as the basal level. After determination of basal blood pressure, rats received VIF intraperitoneally, followed by injection of Ang-II subcutaneously. The rats of the control group received Ang-II after determination of basal blood pressure. Subsequently, blood pressure was measured every 5 minutes over a total of 30 to 45 minutes.
VIF Serum Concentrations in Patients With CKD and Heart Failure In Vivo
Patients with and without CKD were recruited from the University Hospital Essen (Germany). Renal healthy control subjects had an estimated glomerular filtration rate >60 mL·min −1 ·1.73 m −2 and no albuminuria. For biochemical characterization, creatinine, phosphate, serum calcium, total cholesterol, hemoglobin, and albumin were measured with standard autoanalyzer techniques. Patients suffering from heart failure were recruited from the University Hospital Aachen (Germany). Patients investigated suffered from heart failure defined as New York Heart Association stage III and IV treated with 10 mg/d angiotensin-converting enzyme inhibitor (Ramipril). Control probands were characterized by New York Heart Association stage II or less and were treated with angiotensin-converting enzyme inhibitor (ramipril). Blood (2 mL) was collected the blood in tubes. Blood samples were separated as described above.
Statistics
All data are presented as mean±SEM. When error bars do not appear in the figures, errors are within the size of the symbol used there. All statistical analyses were carried out with GraphPad Prism and SAS version 9.4 software. The Wilcoxon-Mann-Whitney test was used for nonparametric statistical tests. Values of P<0.05 (2 sided) were considered to indicate statistical significance. For 2-group comparisons of continuous variables, the Student t test was used. Homoskedasticity was tested with the folded F test, and in case of evidence of unequal variances, the Satterthwaite approximate t test for unequal variances was used. Multigroup comparisons were done with 1-way or 2-way ANOVA with Dunnett or Tukey multiplicity adjustments of post hoc tests for comparisons of multiple groups to a common control or for evaluating all pair-wise comparisons, respectively.
For concentration values, a logarithmic transformation was applied before statistical testing to stabilize variances. If data were not normally distributed even after transformation as evidenced by significant Kolmogorov-Smirnov tests, analysis was based on rank-transformed data. Categorical variables were compared by the Fisher exact tests. Values of P<0.05 (2 sided) were considered to indicate statistical significance.
Results
Isolation and Identification of VIF
The extract of bovine adrenal glands was fractionated by several chromatographic steps as described. A fraction affecting renal vascular tone labeled by the arrow in Figure 1A was further fractionated by a preparative anion exchanger ( Figure 1B) . Each fraction was again screened for vasoregulatory properties. The fractions showing strong vasoregulatory properties (arrow in Figure 1C ) underwent further analysis. The fractions showing strong vasoregulatory properties (arrow in Figure 1C ) underwent further analysis.
The MALDI-TOF/TOF mass spectrum of one of these fractions revealed a molecular mass of 3919 Da (M+H + ; Figure 2A ). The liquid chromatography/ESI mass spectrum of the same fraction revealed a molecular mass of 3919 Da (M+H + ). This peptide was fragmented by MALDI-TOF/ TOF-MS to obtain sequence information for identification by searching in the Mascot database (Table I in the Figure 1 . A, Reverse-phase chromatography of an extract of bovine adrenal glands by using a reverse-phase highperformance liquid chromatography column. Conditions were as follows: Chromolith Performance (100×4.6-mm internal diameter; Merck, Darmstadt, Germany); eluent A, 0.1% trifluoroacetic acid (TFA) in water; eluent B, 80% water-acetonitrile (20:80, vol/vol%); step gradient, 20%, 40%, 60%, 80%, and 100% eluent B; flow rate, 3.0 mL/min; abscissa, retention time (minutes); ordinate, ultraviolet (UV) absorption at 280 nm (arbitrary units {AU]). The fraction labeled with an arrow indicates the fraction that was seen to cause a vasoregulatory effect in the bioassay of isolated perfusion rat kidney. B, Anion-exchange chromatography of the fraction labeled by an arrow in A by using a Superformance 16 column (150-mL volume, Fractogel EMP TMAE, Merck, Darmstadt, Germany; eluent A,: 20 mmol/L K 2 HPO 4 solution in water; eluent B, 20 mmol/L K 2 HPO 4 in 1 mol/L NaCl solution in water); step gradient, 20%, 40%, 60%, 80%, and 100% eluent B; flow rate, 3.0 mL/min; abscissa, retention time (minutes); ordinate, UV absorption at 280 nm (arbitrary units). The fraction labeled with an arrow had a vasoregulatory effect in the bioassay of isolated perfusion rat kidney. C, Reversephase chromatography of a fraction from the anion-exchange chromatography labeled with an arrow in B. Conditions: Chromolith Performance (100×4.6-mm internal diameter, Merck); eluent A, 0.1% TFA in water; eluent B, 80% water-acetonitrile (20:80, vol/vol%); gradient, 0 to 90 minutes: 0% to 90% eluent B; flow rate, 1.0 mL/min; abscissa, retention time (minutes); ordinate, UV absorption at 280 nm (arbitrary units). The fraction labeled with an arrow had a vasoregulatory effect in the bioassay of isolated perfusion rat kidney.
by guest on April 16, 2017 http://circ.ahajournals.org/ Downloaded from online-only Data Supplement). The amino acid sequence HSSYEDELSEVLEKP NDQAEPKE VTEE VSSKDAAE with a molecular mass of 3919 Da (Figure 2A ) yielded the highest Mascot score for the isolated peptide. This amino acid sequence belongs to the amino acids 97 to 131 of chromogranin A ( Figure 2B ). To further substantiate this amino acid sequence, we compared the MS/MS fragment mass spectrum with that obtained from the synthetic peptide. After resynthesis of the peptide, a comparison of MS fragments from the synthetic and endogenous peptide revealed the identity (data not shown). Because of the vasoregulatory properties of the isolated peptide described in the following sections, we named the peptide vasoconstriction-inhibiting factor (VIF).
To examine whether VIF is proteolyzed from intracellular or extracellular chromogranin A, we isolated granules of adrenal glands. We were able to detect the molecular mass of 3919 (M+H + ) by both ESI-MS ( Figure 2C ) and MALDI-TOF/TOF in fractions of granules of bovine adrenal, which corresponds to the molecular weight of bovine VIF. The corresponding MALDI-TOF/TOF fragmentation mass spectra confirmed the identity of the amino acid sequence of the underlying endogenous cofactor of Ang-II (Table I in the online-only Data Supplement). Each signal was attributable to a fragment of bovine VIF, suggesting that VIF is a component of granules of adrenal glands. Because carbachol stimulates the release of VIF from adrenal glands ( Figure 2D ) significantly, we assume that the release of VIF from adrenal glands may be partly mediated by the autonomous nervous system.
Inhibitory Properties of VIF
Next, we characterized the inhibitory properties of VIF using the isolated perfused rat kidney assay. Figure 2E demonstrates the effect of VIF on the vasoconstriction caused by increasing concentrations of Ang-II. The graph illustrates the vasoconstriction caused by high Ang-II concentrations in the presence and the absence of VIF (10 -6 mol/L). VIF causes a decrease in both the half-maximal effective concentration and the maximal effect of Ang-II. Neither the scrambled peptide AESHESSEMVSVDEEELKPNQDGEQVKELSFSEAL (peptide A) nor the truncated peptides EDELSEVLE (peptide B), KEAVEEP (peptide C), or SSKDVME (peptide D; each 10 -6 mol/L) caused a significant effect on the vasoconstrictive effect of an Ang-II bolus injection ( Figure 2F ). The comparison of the amino acid of the endogenous peptide, scrambled peptide, and truncated peptides is given in Figure I in the online-only Data Supplement.
Human Plasma Concentration of VIF
To isolate VIF from human plasma, we used the same chromatographic protocol as for the isolation of bovine VIF from adrenal glands secretome. We isolated 1 fraction from plasma of a renal healthy donor ( Figure 3A ) with a molecular mass of 3907 (M+H + ; Figure 3B ). The amino acid sequence of the underlying peptide was identified as HSGFEDELSEV LENQSSQAEL KEAVEEP SSKDVME ( Figure 3C and Table  II in the online-only Data Supplement) by using MALDI-TOF/ TOF-MS and liquid chromatography/ESI-MS/MS-MS. The amino acid sequence corresponds to the amino acid sequence of the human VIF peptide from human chromogranin A ( Figure 3C ) but has no similarities to angiotensin peptides like Ang-I (1-10; DRVYIHP FHL), Ang-1 to -9 (DRVYIHPFH), Ang-II (1-8; DRVYIHPF), Ang-III (2-8; RVYIHPF), Ang-IV (3-8; VYIHPF), Ang-1 to -7 (DRVYIHP), 20 angioprotectin (PEVYIHPF), 10 or Ang-A ARVYIHPF). 21 The concentration of human VIF in plasma from patients with and without CKD ( Table 1) and patients with or without heart failure ( Table 2 ) was quantified by highly sensitive and specific MS-based approach because a specific antibody for VIF is not yet available. The VIF concentration was significantly higher in patients with advanced CKD (CKD stage 5, including patients on hemodialysis) than it was in control patients with normal renal function (1.87±0.52 versus 0.57±0.09 μmol/L; P<0.001; Figure 3D ). In addition, VIF concentrations were significantly increased in patients with heart failure compared with control Figure 3E ). We assume that this increased VIF plasma concentration is a compensatory response to the increased blood pressure, aiming toward end-organ protection. Next, we incubated enzymes from adrenal glands immobilized to Sepharose beads with chromogranin A to analyze the principal mechanism of the VIF biosynthesis from chromogranin A. Figure 3F demonstrates an enzymatic digestion of chromogranin A to VIF by adrenal enzymes.
The inhibitory effect of VIF on Ang-II-induced vasoconstriction was made evident when VIF concentrations were kept constant and Ang-II concentrations were varied ( Figure 4A ). The specificity of the effect was demonstrated by using increasing concentrations of epinephrine because VIF had no effect on the vasoconstrictive effect of epinephrine ( Figure 4B ). In the presence of L-NAME, which caused a slight increase in the vasoconstrictive properties of Ang-II ( Figure 4C ), the effect of VIF was still maintained (Figure 4D ), although the effects of VIF were less pronounced.
The next experiments were designed to investigate the receptor that mediates the vasoregulatory effects of VIF. To examine the role of AT2 receptors, the isolated perfused rat kidneys were perfused with the AT2 receptor blocker PD 123,319 (10 -5 mol/L). PD 123,319 increased the vasoconstrictive effect of Ang-II and abolished the effect of VIF ( Figure 4E and 4F) .
The peptide VIF decreased the vasoconstrictive effects of Ang-II in a dose-dependent manner ( Figure 5A ). The EC 50 value of the VIF effect was calculated to be −11.07±0.5 (log mol/L).
Next, the effects of VIF on the vasoconstrictive state of isolated aortic rings precontracted by Ang-II in the absence and presence of L-NAME were validated. VIF reduced Ang-II-induced constrictions by ≈30%. Although this vasodilative effect of VIF was not significantly modified by L-NAME, the corresponding effect of the selective agonist Compound C-21 was significantly decreased in the presence of L-NAME ( Figure 5B) .
Afterward, human microvascular endothelial cells expressing the AT2 receptor were exposed to fluorescencelabeled VIF. The presence of the fluorescence-labeled VIF caused a marked increase in the fluorescence of the human microvascular endothelial cells ( Figure 5C ), which was significantly decreased in the presence of PD123,319, the selective antagonist of AT2 receptors. This illustrates the affinity of VIF to the receptor of interest in terms of a noncompetitive inhibition.
Screening for Ang-II-induced signaling that may altered by VIF showed that VIF impaired Ang-II-induced phosphorylation of p38 mitogen-activated protein kinase ( Figure 5D ) but had no effects on ERK1/2 (data not shown). 
In Vivo Experiments
After characterizing the inhibitory effect of VIF on vascular constriction in vitro, we investigated the inhibitory effect of VIF on blood pressure in vivo by using wild-type rats. Intraperitoneal administration of VIF after 10 minutes produced a significant diminution of Ang-II-induced increase in blood pressure ( Figure 5E ). Subsequent intraperitoneal administration of VIF in long-term experiments also showed a significant decrease in the Ang-II-induced increase in blood pressure over 12 days ( Figure 5F ).
Discussion
In the present study, we isolated and identified a new chromogranin A peptide that we named VIF. VIF, but neither a scrambled peptide nor truncated peptides, diminishes the vasoconstrictive effects of the potent vasoconstrictor Ang-II. Chromogranin A is secreted in neuroendocrine and endocrinal tissue. 22 Chromogranin A is a precursor protein for several biological active peptides with a vasoregulatory function such as vasostatin-I (human CHGA 1-97), [23] [24] [25] vasostatin-II (human CHGA 1-113), 25, 26 and catestatin (human CHGA 352-372). 23, 27 Vasostatin I and vasostatin II inhibit the vasoconstrictive effects of human vessels. 22 Vasostatin I is a regulator of adrenergic-induced cardiac inotropic effect. 28 Catestatin is strongly involved in cardiovascular pathophysiology: chromogranin A concentrations in hypertensives are elevated and concentrations of catestatin are diminished compared with those of cardiovascular healthy controls. 29 Because VIF is released after stimulation from granules of adrenal glands, we assume that the release of VIF from adrenal glands may be partly mediated by the autonomous nervous system and may be involved in the cardiovascular regulation. The EC 50 values of VIF in the bioassay used in the study suggest a role for VIF in the regulation of the blood pressure. The VIF concentrations in human plasma are obviously sufficient to influence Ang-II-induced vasoconstriction caused by Ang-II but apparently not other known vasoregulators.
The AT2 receptor blocker PD123,319 abolished the vasodilatory effect of VIF, suggesting that the dilatory effect of VIF is mediated by the AT2 receptor. Because the vascular effects of the AT2 receptor are mediated mostly by nitric oxide, the effects of L-NAME are largely in line with those of AT2 receptor blockade. However, L-NAME did not abolish the VIF effects completely. This is in accordance with the pertinent literature showing that the AT2 receptor exerts its vascular actions not only via nitric oxide but also, for example, via attenuation of RhoA/Rho kinase activation by dephosphorylation 30 (see Lemarié and Schiffrin 31 for a review). VIF acts in terms of a noncompetitive inhibitor at the AT2 receptor. However, because there is still some affinity to human microvascular endothelial cells in the presence of PD123,319, the involvement of an additional receptor may indeed be possible.
There are also numerous reports showing that the p38 mitogen-activated protein kinase pathway is involved in the AT2 receptor signaling. [32] [33] [34] [35] Thus, in accordance with the pertinent literature, our experiments show that this pathway is also one target of VIF-induced modulation of Ang-II-induced vasoconstriction. Because VIF has no effect on ERK 1/2, the ERK pathway is obviously not essential for the vasoregulatory effects of VIF.
To evaluate the in vivo relevance of VIF, the effect of a subcutaneous Ang-II injection with and without a subsequent intraperitoneal VIF application was quantified. The latter application of VIF caused a decrease in the effect of Ang-II on blood pressure of ≈25%. Because the effects of long-term Ang-II infusion were also modified by VIF, an inhibition of sustained hypertension is likely. Adrenal glands are capable of synthesizing VIF enzymatically and releasing VIF as an active compound after stimulation. The plasma concentration of the chromogranin A peptide VIF is in the same range of other chromogranin A peptides such as vasostatin-I. 36, 37 The plasma concentration of VIF was increased in patients suffering from either CKD or heart failure. This agrees well with reports showing that the plasma concentration of its precursor, chromogranin A, is increased in patients suffering from heart failure and renal failure. 38, 39 These findings underline the fact that VIF is involved in the Ang-II-mediated vasoregulation. Therefore, we suggest that VIF may be a protective endogenous factor counteracting the harmful effects of Ang-II in those patients. Increased VIF plasma levels in chronic renal failure might confer some protection against the detrimental actions of Ang-II in this condition. VIF modulates the vasoconstrictive effects of Ang-II in a wide physiologically and pathophysiologically relevant concentration range; however, in future clinical studies, the effect of VIF in human pathophysiology should be analyzed further. It may be speculated that VIF administration might offer a further therapeutic tool to limit the detrimental effects of neurohumoral counterregulation in conditions such as renal failure and heart failure.
Conclusions
The findings of the present study may be of interest for several reasons. First, the results demonstrate for the first time a chromogranin A peptide that modulates the vasoconstrictive action Ang-II. Second, increased VIF plasma concentration may modulate the harmful effects of Ang-II. Finally, the affinity of VIF to the AT2 receptor demonstrates the impact of this receptor on the regulation of blood pressure. Further studies are required to analyze the interactions of VIF with Ang-II metabolism. Likewise, the interactions of VIF with other angiotensin peptides such as Ang-1 to -7, 40 angioprotectin, 10 and alamandine 41 will have to be studied. It may be expected that the actions of VIF will add to the complexity of vasoregulation. 
CLINICAL PERSPECTIVE
In this study, we identified and evaluated a circulating peptide secreted by adrenal glands that acts as cofactor of angiotensin II-induced vasoregulation. This circulating peptide modulates the vasoconstrictive effects of angiotensin II by acting on the angiotensin II type 2 receptor. Acting on the angiotensin II type 2 receptor, vasoconstriction-inhibiting factor (VIF) levels may be an important factor in the context of vasoregulation. On the basis of the vasoregulatory effects on the angiotensin II actions, the peptide was named VIF. Plasma VIF concentrations are increased in chronic renal failure and heart failure. It is likely that this increase in VIF may serve as a counterregulatory effect to defend against hypertension. Clinical studies should reveal whether a higher VIF concentration is associated with better control of blood pressure or a decreased cardiovascular mortality in patients with chronic kidney disease. The results of this study may help us to understand the pathophysiology of renal and heart failure. The identification of this peptide might form a basis for the development of new strategies for the prevention and treatment of cardiovascular diseases with this peptide as a target. However, further studies are required to analyze the interactions of VIF with the overall angiotensin metabolism. Likewise, the interactions of VIF with other angiotensin peptides such as angiotensin 1 to angiotensin 7, angioprotectin, and alamandine will have to be studied. It may be expected that the actions of VIF will add to the complexity of vasoregulation. y8  b29  y7  b30  y6  b31  y5  b32  y4  b33 3628.69 y3 b34 y2 b35 y1
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A: CHEMICALS HPLC water (gradient grade), acetonitrile (ACN) and magnesium chloride-hexahydrate were purchased from Merck (Germany), Dulbecco's Modified Eagle's Medium (DMEM Medium) from Biochrom AG (Germany), and all other substances from Sigma-Aldrich (Germany).
MECHANICAL DESINTEGRATION AND EXTRACTION
Bovine adrenal glands were cut into pieces weighing about 1 g, snap-frozen in liquid nitrogen for 30 min, stored at -80°C for 12 hours and subsequently lyophilized. The freeze-dried adrenal glands were mechanically pulverized at 4°C. 70 ml of 0.6 mM perchloric acid with a temperature of 4°C
were added to 700 g of pulverized adrenal glands. The resulting mixture was homogenized by using an Ultra-Turrax (9,500 U min -1 ) for 1 min at 4°C. This procedure was repeated 10 times. The homogenate was centrifuged at 2,000  g for 15 min at 4°C. The pH of the supernatant was adjusted The chromatographies were performed on a BioLogic DuoFlow HPLC-machine (Bio-Rad, Munich, Germany) with a UV-detector using a wavelength of 280 nm. After lyophilization, the fractions were resuspended in 10 µl of H 2 O. Each chromatography fraction was screened for vasoregulatory properties by using the bioassay of the isolated perfused rat kidney as described below.
ISOLATED PERFUSED RAT KIDNEY BIOASSAY
Male Wistar-Kyoto rats were anesthetized with isoflurane for 3 min (FORENE, Abbott, Germany).
Subsequently the rats received urethane 1.5 g kg -1 intraperitoneally. After negative nociceptive reflexes were obtained the abdominal cavity was opened by a Y-shaped incision. The aorta and the right kidney were isolated by using blunt dissection in order to avoid injuries. On the infrarenal aorta and right renal artery ligatures were placed. A polyethylene catheter (20-gauge) was inserted in the infrarenal aorta distal from the ligature and gently pushed through the renal artery without interrupting blood flow. Directly after the insertion of the catheter, 250 IU of heparin sodium (Biochrom, Berlin, Germany) were injected. The kidney was connected to the perfusion system after excision (Hugo Sachs Electronic, Germany). The perfusion pressure was monitored continuously by use of a transducer (Statham P23 GB, Siemens) connected to a bridge amplifier (Hugo Sachs).
The perfusion procedure generally followed the description given by van der Giet et al. 19 . Briefly, the isolated rat kidney was perfused by using a peristaltic pump in a single-pass system with a solu- ) and Ang II (10 -6 mol l -1 ) were both used as positive controls for vasoconstrictive response of the isolated kidney.
Male sprague dawley rats (300-400g) were dispatch by isoflurane overdose. The thoracic aorta was rapidly removed and immersed in cold Krebs-Henseleit solution aerated with 95% O 2 and 5% CO 2 .
The aorta was cleaned of connective tissue and divided in 8 rings, thickness 2 mm each. The aortic rings were suspended in a Automatic Organ Bath (Panlab, Harvard Apparatus, Germany) and changes in force were recorded using an automated system (ADInstruments, Germany) and analysed by Powerlab 8/30 Software (ADInstruments, Germany). Each aortic ring was preload of 3g
and equilibrated for 60 min. After equilibration for 60 min, the aortic rings were exposed to Ang II ions were analyzed in the reflector mode using delayed ion extraction. Fragment ion spectra were recorded using the LIFT option of the instrument. The calibration constants were determined using standard peptides prepared on positions adjacent to the sample, resulting in an error of <100 ppm for the recorded mass spectra. Peptide identification using the obtained fragment ion mass data was performed using the software package Mascot (Matrix Science, UK) as well as the RapiDeNovo sequencing tool (Ver. 3.0.1, Bruker-Daltronic, Germany).
ELECTROSPRAY-IONISATION-MASS-SPECTROMETRY
In addition to the MALDI-mass-spectrometry, the fractions of interest were analyzed by using a liquid-chromatography/electrospray-mass-spectrometry (ESI) MS/MS technique. Two capillary HPLC-pumps (G1376A, Agilent, Germany) with micro vacuum degasser (G1379B, Agilent, Germany), an automatic micro-well-plate autosampler (G1377A, Agilent, Germany), and a diode array multi-wavelength detector (G1365D Agilent, Germany) were used for the chromatography. 
ISOLATION OF GRANULES FROM BOVINE ADRENAL GLANDS
Fresh bovine adrenal glands were obtained on ice from a local slaughterhouse and cleaned of lipid matter, and then the adrenal glands were dissected. The granules were obtained from the adrenal glands according to established techniques 15, 16 . Briefly, 50 ml of 0.32 mol l -1 sucrose were added to the adrenal glands. The suspension was homogenized with an ultra-turrax at 4°C (750 rpm) and the homogenate was centrifuged at 800g at 4°C for 10 min. The supernatant was centrifuged again at 10,000  g and 4°C for 20 min. To the supernatant, 50 ml of 1.6 mol l -1 sucrose were added and the suspension was centrifuged at 100,000  g and 4°C for 45 min. The pellet was resuspended in 10 ml of water and divided into two aliquots. For the extraction of VIF from the granules carbachol (10 -5 mol l -1 ) was added to one aliquot. PBS was added to the second aliquot as a negative control condition. The suspension was thoroughly mixed with a vortex mixer for 5 min at room temperature. The supernatant was analyzed by electrospray-ionization mass-spectrometry as described above.
PEPTIDE SYNTHESIS
After mass-spectrometric identification, the peptide VIF and the scrambled peptide were synthe- 
IN-VIVO EFFECTS OF SYNTHETIC PEPTIDE VIF
Wistar rats weighing 200 g were used to investigate the effect of synthetic VIF in-vivo. All animals had free access to standard rat diet and tap water ad libitum. Mean arterial pressure was measured in conscious animals by means of a tail-cuff sphygmomanometer (LE 5001 Non-invasive blood pressure system, Spain). To prevent stress, animals were trained for 3 days before starting the measurement and were pre-warmed at 30ºC with a heater (LE5610, Spain). Five determinations were made and the mean value was used as the basal level. After determination of basal blood pressure, rats received 5 mg kg -1 of VIF intraperitoneally, followed by injection of 100 µg kg -1 of Ang II subcutaneously. The rats of the control group received Ang II (100 µg kg -1 , subcutaneously) (Sigma-Aldrich, USA) after determination of basal blood pressure. Subsequently, blood pressure was measured every 5 min over a total of 30-45 minutes.
VIF SERUM CONCENTRATIONS IN CKD PATIENTS IN-VIVO
Patients with and without were recruited from the University Hospital Essen (Germany) after the local Ethics Committee had granted project approval and after patients had given written consent.
Patients (N=10) investigated suffered from CKD stage 5 according to KDOQI -defined as estimated glomerular filtration rate (eGFR MDRD) <15 ml/min/1.73m 2 or dependent on hemodialysis.
CKD stage 5D patients were treated by hemodialysis. Renal healthy control subjects had eGFR>60 ml/min/1.73 m 2 . Control patients without CKD (n=9) had eGFR>60 ml/min/1.73 m 2 and no albuminuria. For biochemical characterisation creatinine, phosphate, serum calcium, total cholesterol, hemoglobin and albumin were measured using standard auto analyser techniques. Two ml of blood were collected in tubes containing K 2 -EDTA (7.2 mg). Blood samples were immediately separated by centrifugation (2.000 U/min and 4°C) for isolation of plasma and kept frozen until all samples of the collective could be measured by the mass-spectrometric approach as described above.
VIF SERUM CONCENTRATIONS IN HEART FAILURE PATIENTS IN-VIVO
Patients suffering from heart failure were recruited from the University Hospital Aachen (Germany) after the local Ethics Committee had granted project approval and after patients had given
